ERBB2 and breast neoplasm: Mitogenic signaling is considered an important driving factor of breast tumorigenesis, while the resistance to tyrosine kinase inhibitor (TKI), such as lapatinib, is a commonly seen problem within the clinical treatment of HER2-amplified breast tumors.